WASHINGTON (dpa-AFX) - AbbVie (ABBV) has submitted applications seeking approval for SKYRIZI to the FDA and for SKYRIZI to the European Medicines Agency for the treatment of adults with active psoriatic arthritis. The submissions were supported by two pivotal phase 3 studies, KEEPsAKE-1 and KEEPsAKE-2. The safety profile of SKYRIZI in these studies was generally consistent with the safety profile of SKYRIZI in plaque psoriasis.
SKYRIZI is an interleukin-23 (IL-23) inhibitor that selectively blocks IL-23 by binding to its p19 subunit. SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.
Copyright RTT News/dpa-AFX
ABBVIE-Aktie komplett kostenlos handeln - auf Smartbroker.de